Company intelligence / Profile preview
Stand Up Therapeutics
Seoul, South Korea
- Ownership
- Private
- Development stage
- Other
01
Overview
STUP-001 (spinal cord injury gene therapy) entered Phase 1/2 clinical trials with initial dosing of paraplegia patients in early 2023. No published efficacy data yet. Four other pipeline programs are preclinical.
- Therapeutic areas
- PsychiatryNeurologyCardiovascular
- Modalities
- Gene therapyAdeno-associated virus-based therapyCell therapy
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
VectorBuilder
Beyond the preview
Go deeper on Stand Up Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Stand Up Therapeutics.